Clifford J Rosen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8826077/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The effect of short-term high-caloric feeding and fasting on bone microarchitecture. Bone, 2022, 154, 116214.	1.4	3
2	The health effects of vitamin D supplementation: evidence from human studies. Nature Reviews Endocrinology, 2022, 18, 96-110.	4.3	181
3	Calorie restriction improves lipid-related emerging cardiometabolic risk factors in healthy adults without obesity: Distinct influences of BMI and sex from CALERIEâ,,¢ a multicentre, phase 2, randomised controlled trial. EClinicalMedicine, 2022, 43, 101261.	3.2	26
4	Audio Interview: Studying Long Covid. New England Journal of Medicine, 2022, 386, e20.	13.9	3
5	Insulin-like growth factor binding protein 2 null mice (Igfbp2â^'/â^') are protected against trabecular bone loss after vertical sleeve gastrectomy. Surgical Endoscopy and Other Interventional Techniques, 2022, , .	1.3	0
6	Reply to â€~The emerging evidence for non-skeletal health benefits of vitamin D supplementation in adults'. Nature Reviews Endocrinology, 2022, , .	4.3	0
7	FSH blockade improves cognition in mice with Alzheimer's disease. Nature, 2022, 603, 470-476.	13.7	131
8	Post-acute sequelae of COVID-19: A metabolic perspective. ELife, 2022, 11, .	2.8	51
9	Parathyroid hormone (PTH) regulation of metabolic homeostasis: An old dog teaches us new tricks. Molecular Metabolism, 2022, 60, 101480.	3.0	19
10	EXTENSIVE EXPERTISE IN ENDOCRINOLOGY: My quarter century quest to understand the paradox of marrow adiposity. European Journal of Endocrinology, 2022, 187, R17-R26.	1.9	2
11	Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis. Nature Reviews Endocrinology, 2021, 17, 31-46.	4.3	71
12	Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype. Cancer Research, 2021, 81, 634-647.	0.4	50
13	Serum FSH Is Associated With BMD, Bone Marrow Adiposity, and Body Composition in the AGES-Reykjavik Study of Older Adults. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1156-e1169.	1.8	30
14	Bone Marrow Adipocytes: A Link between Obesity and Bone Cancer. Cancers, 2021, 13, 364.	1.7	19
15	Liver homeostasis is maintained by midlobular zone 2 hepatocytes. Science, 2021, 371, .	6.0	154
16	Vitamin D Supplementation for Prevention of Cancer: The D2d Cancer Outcomes (D2dCA) Ancillary Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2767-2778.	1.8	20
17	The role of Zfp467 in mediating the pro-osteogenic and anti-adipogenic effects on bone and bone marrow niche. Bone, 2021, 144, 115832.	1.4	9
18	A regulatory variant at 3q21.1 confers an increased pleiotropic risk for hyperglycemia and altered bone mineral density. Cell Metabolism, 2021, 33, 615-628.e13.	7.2	28

#	Article	IF	CITATIONS
19	Plasma Concentrations of Per- and Polyfluoroalkyl Substances and Body Composition From Mid-Childhood to Early Adolescence. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3760-e3770.	1.8	12
20	STEP 1 for Effective Weight Control — Another First Step?. New England Journal of Medicine, 2021, 384, 1066-1067.	13.9	10
21	From gut to blood: the travels and travails of vitamin D supplementation. American Journal of Clinical Nutrition, 2021, 114, 831-832.	2.2	4
22	Bone marrow adipose tissue composition following high-caloric feeding and fasting. Bone, 2021, 152, 116093.	1.4	11
23	Systems genetics in diversity outbred mice inform BMD GWAS and identify determinants of bone strength. Nature Communications, 2021, 12, 3408.	5.8	31
24	Dual targeting of salt inducible kinases and CSF1R uncouples bone formation and bone resorption. ELife, 2021, 10, .	2.8	12
25	The dynamics of human bone marrow adipose tissue in response to feeding and fasting. JCI Insight, 2021, 6, .	2.3	29
26	FSH Level and Changes in Bone Mass and Body Composition in Older Women and Men. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2876-2889.	1.8	9
27	Loss of function of lysosomal acid lipase (LAL) profoundly impacts osteoblastogenesis and increases fracture risk in humans. Bone, 2021, 148, 115946.	1.4	8
28	Bone marrow adipose tissue: New insights and clinical correlates from Best Practices. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101563.	2.2	0
29	PFAS and Potential Adverse Effects on Bone and Adipose Tissue Through Interactions With PPARÎ ³ . Endocrinology, 2021, 162, .	1.4	29
30	Osteoporosis and Dementia: Establishing a Link. Journal of Bone and Mineral Research, 2021, 36, 2103-2105.	3.1	8
31	Bone and fat. , 2021, , 833-846.		Ο
32	Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. Journal of Bone and Mineral Research, 2020, 35, 36-52.	3.1	146
33	Lipids in the Bone Marrow: An Evolving Perspective. Cell Metabolism, 2020, 31, 219-231.	7.2	59
34	Marrow Adipocytes: Origin, Structure, and Function. Annual Review of Physiology, 2020, 82, 461-484.	5.6	44
35	Greater Bone Marrow Adiposity Predicts Bone Loss in Older Women. Journal of Bone and Mineral Research, 2020, 35, 326-332.	3.1	37
36	AGS and NIA Benchâ€ŧo Bedside Conference Summary: Osteoporosis and Soft Tissue (Muscle and Fat) Disorders. Journal of the American Geriatrics Society, 2020, 68, 31-38.	1.3	13

#	Article	IF	CITATIONS
37	The Lipid Handling Capacity of Subcutaneous Fat Is Programmed by mTORC2 during Development. Cell Reports, 2020, 33, 108223.	2.9	13
38	First-in-class humanized FSH blocking antibody targets bone and fat. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28971-28979.	3.3	35
39	Finerenone — Halting Relative Hyperaldosteronism in Chronic Kidney Disease. New England Journal of Medicine, 2020, 383, 2285-2286.	13.9	17
40	Myosteatosis in the Context of Skeletal Muscle Function Deficit: An Interdisciplinary Workshop at the National Institute on Aging. Frontiers in Physiology, 2020, 11, 963.	1.3	190
41	Bariatric Surgery and Restoration of Insulin Sensitivity — It's Weight Loss. New England Journal of Medicine, 2020, 383, 777-778.	13.9	9
42	Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. Journal of Orthopaedic Trauma, 2020, 34, e125-e141.	0.7	10
43	The inherent challenges of classifying senescence—Response. Science, 2020, 368, 595-596.	6.0	5
44	Deletion of α-Synuclein in Prrx1-positive cells causes partial loss of function in the central nervous system (CNS) but does not affect ovariectomy induced bone loss. Bone, 2020, 137, 115428.	1.4	3
45	Reporting Guidelines, Review of Methodological Standards, and Challenges Toward Harmonization in Bone Marrow Adiposity Research. Report of the Methodologies Working Group of the International Bone Marrow Adiposity Society. Frontiers in Endocrinology, 2020, 11, 65.	1.5	53
46	Pathological Conversion of Mouse Perivascular Adipose Tissue by Notch Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2227-2243.	1.1	25
47	Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 587-594.	1.8	214
48	Perivascular osteoprogenitors are associated with transcortical channels of long bones. Stem Cells, 2020, 38, 769-781.	1.4	19
49	Parkinson's disease and osteoporosis: basic and clinical implications. Expert Review of Endocrinology and Metabolism, 2020, 15, 185-193.	1.2	11
50	Saturated and Unsaturated Bone Marrow Lipids Have Distinct Effects on Bone Density and Fracture Risk in Older Adults. Journal of Bone and Mineral Research, 2020, 37, 700-710.	3.1	13
51	Emerging Aspects of the Body Composition, Bone Marrow Adipose Tissue and Skeletal Phenotypes in Type 1 Diabetes Mellitus. Journal of Clinical Densitometry, 2019, 22, 420-428.	0.5	20
52	Per- and Polyfluoroalkyl Substance Plasma Concentrations and Bone Mineral Density in Midchildhood: A Cross-Sectional Study (Project Viva, United States). Environmental Health Perspectives, 2019, 127, 87006.	2.8	35
53	The mitophagy receptor Bcl-2–like protein 13 stimulates adipogenesis by regulating mitochondrial oxidative phosphorylation and apoptosis in mice. Journal of Biological Chemistry, 2019, 294, 12683-12694.	1.6	35
54	Response to Letter to the Editor: "Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline― Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3537-3538.	1.8	8

#	Article	IF	CITATIONS
55	To help aging populations, classify organismal senescence. Science, 2019, 366, 576-578.	6.0	42
56	Early reduced bone formation following burn injury in rats is not inversely related to marrow adiposity. Osteoporosis and Sarcopenia, 2019, 5, 84-86.	0.7	1
57	Vitamin D Supplementation and Prevention of Type 2 Diabetes. New England Journal of Medicine, 2019, 381, 520-530.	13.9	423
58	Traveling down the Long Road to Type 1 Diabetes Mellitus Prevention. New England Journal of Medicine, 2019, 381, 666-667.	13.9	15
59	Resistance to visceral obesity is associated with increased locomotion in mice expressing an endothelial cellâ€specific fibroblast growth factor 1 transgene. Physiological Reports, 2019, 7, e14034.	0.7	4
60	Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1595-1622.	1.8	470
61	A novel mouse model overexpressing <i>Nocturnin</i> results in decreased fat mass in male mice. Journal of Cellular Physiology, 2019, 234, 20228-20239.	2.0	12
62	Clinical Credence — SGLT2 Inhibitors, Diabetes, and Chronic Kidney Disease. New England Journal of Medicine, 2019, 380, 2371-2373.	13.9	22
63	Senescent and apoptotic osteocytes and aging: Exercise to the rescue?. Bone, 2019, 121, 255-258.	1.4	20
64	Association of Receiving Multiple, Concurrent Fracture-Associated Drugs With Hip Fracture Risk. JAMA Network Open, 2019, 2, e1915348.	2.8	19
65	Metabolic programming determines the lineage-differentiation fate of murine bone marrow stromal progenitor cells. Bone Research, 2019, 7, 35.	5.4	30
66	Mitochondrial Function Is Compromised in Cortical Bone Osteocytes of Long-Lived Growth Hormone Receptor Null Mice. Journal of Bone and Mineral Research, 2019, 34, 106-122.	3.1	27
67	Body composition and bone mineral density in childhood. Bone, 2019, 121, 9-15.	1.4	27
68	VITAL Signs for Dietary Supplementation to Prevent Cancer and Heart Disease. New England Journal of Medicine, 2019, 380, 91-93.	13.9	25
69	Progenitor recruitment and adipogenic lipolysis contribute to the anabolic actions of parathyroid hormone on the skeleton. FASEB Journal, 2019, 33, 2885-2898.	0.2	54
70	Bone Marrow Adiposity- Special Edition. Bone, 2019, 118, 1.	1.4	1
71	Development of a 3D bone marrow adipose tissue model. Bone, 2019, 118, 77-88.	1.4	49
72	G-CSF partially mediates effects of sleeve gastrectomy on the bone marrow niche. Journal of Clinical Investigation, 2019, 129, 2404-2416.	3.9	32

#	Article	IF	CITATIONS
73	Changes in marrow adipose tissue with short-term changes in weight in premenopausal women with anorexia nervosa. European Journal of Endocrinology, 2019, 180, 189-199.	1.9	19
74	Standardised Nomenclature, Abbreviations, and Units for the Study of Bone Marrow Adiposity: Report of the Nomenclature Working Group of the International Bone Marrow Adiposity Society. Frontiers in Endocrinology, 2019, 10, 923.	1.5	34
75	MON-098 FSH and Body Composition in Older Adults. Journal of the Endocrine Society, 2019, 3, .	0.1	0
76	Magnetic resonance imaging and spectroscopy evidence of efficacy for adrenal and gonadal hormone replacement therapy in anorexia nervosa. Bone, 2018, 110, 335-342.	1.4	10
77	Epitope-specific monoclonal antibodies to FSHÎ ² increase bone mass. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2192-2197.	3.3	65
78	Sexual Dimorphism and the Origins of Human Spinal Health. Endocrine Reviews, 2018, 39, 221-239.	8.9	18
79	40 YEARS OF IGF1: Insulin-like growth factors: actions on the skeleton. Journal of Molecular Endocrinology, 2018, 61, T115-T137.	1.1	142
80	Osteoblast-like MC3T3-E1 Cells Prefer Glycolysis for ATP Production but Adipocyte-like 3T3-L1 Cells Prefer Oxidative Phosphorylation. Journal of Bone and Mineral Research, 2018, 33, 1052-1065.	3.1	71
81	Isolation, Culture, and Differentiation of Bone Marrow Stromal Cells and Osteoclast Progenitors from Mice. Journal of Visualized Experiments, 2018, , .	0.2	52
82	Actions of pituitary hormones beyond traditional targets. Journal of Endocrinology, 2018, 237, R83-R98.	1.2	45
83	The skeletal cellâ€derived molecule sclerostin drives bone marrow adipogenesis. Journal of Cellular Physiology, 2018, 233, 1156-1167.	2.0	116
84	Reduced Serum IGF-1 Associated With Hepatic Osteodystrophy Is a Main Determinant of Low Cortical but Not Trabecular Bone Mass. Journal of Bone and Mineral Research, 2018, 33, 123-136.	3.1	18
85	Sex hormones are negatively associated with vertebral bone marrow fat. Bone, 2018, 108, 20-24.	1.4	20
86	Clinical implications of bone marrow adiposity. Journal of Internal Medicine, 2018, 283, 121-139.	2.7	159
87	A Renewable Source of Human Beige Adipocytes for Development of Therapies to Treat Metabolic Syndrome. Cell Reports, 2018, 25, 3215-3228.e9.	2.9	46
88	Conflicts of Interest in Clinical Practice Guidelines: Accelerating an Evolution. An Endocrine Society Consensus Statement*. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4339-4342.	1.8	3
89	Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. Diabetes Care, 2018, 41, 1590-1599.	4.3	16
90	A Reliable Diagnostic Test for Hypotonic Polyuria. New England Journal of Medicine, 2018, 379, 483-484.	13.9	9

#	Article	IF	CITATIONS
91	Chronic Kidney Disease Is Associated With Greater Bone Marrow Adiposity. Journal of Bone and Mineral Research, 2018, 33, 2158-2164.	3.1	23
92	FSH, Bone Mass, Body Fat, and Biological Aging. Endocrinology, 2018, 159, 3503-3514.	1.4	40
93	Lorcaserin — Elixir or Liability?. New England Journal of Medicine, 2018, 379, 1174-1175.	13.9	2
94	Sympathetic Î ² 1-adrenergic signaling contributes to regulation of human bone metabolism. Journal of Clinical Investigation, 2018, 128, 4832-4842.	3.9	71
95	Integrating GWAS and Co-expression Network Data Identifies Bone Mineral Density Genes SPTBN1 and MARK3 and an Osteoblast Functional Module. Cell Systems, 2017, 4, 46-59.e4.	2.9	124
96	Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate. Cell Metabolism, 2017, 25, 661-672.	7.2	308
97	Inhibition of osteoclast differentiation and collagen antibody-induced arthritis by CTHRC1. Bone, 2017, 97, 153-167.	1.4	28
98	A perspective on malignancy in the marrow. Journal of Cellular Physiology, 2017, 232, 3218-3220.	2.0	0
99	Normal bone density and trabecular bone score, but high serum sclerostin in congenital generalized lipodystrophy. Bone, 2017, 101, 21-25.	1.4	12
100	Exercise reverses pain-related weight asymmetry and differentially modulates trabecular bone microarchitecture in a rat model of osteoarthritis. Life Sciences, 2017, 180, 51-59.	2.0	13
101	Fat and Bone: Where are We Now?. Calcified Tissue International, 2017, 100, 431-432.	1.5	2
102	Energy Metabolism of the Osteoblast: Implications for Osteoporosis. Endocrine Reviews, 2017, 38, 255-266.	8.9	272
103	Bone–Fat Interaction. Endocrinology and Metabolism Clinics of North America, 2017, 46, 41-50.	1.2	34
104	Mechanisms of marrow adiposity and its implications for skeletal health. Metabolism: Clinical and Experimental, 2017, 67, 106-114.	1.5	62
105	Connecting Bone and Fat: the Potential Role for Sclerostin. Current Molecular Biology Reports, 2017, 3, 114-121.	0.8	37
106	Blocking FSH induces thermogenic adipose tissue and reduces body fat. Nature, 2017, 546, 107-112.	13.7	250
107	Bone Marrow Adipose Tissue: The First 40 Years. Journal of Bone and Mineral Research, 2017, 32, 1153-1156.	3.1	13
108	Addressing the Crisis in the Treatment of Osteoporosis: A Path Forward. Journal of Bone and Mineral Research, 2017, 32, 424-430.	3.1	134

#	Article	IF	CITATIONS
109	Spontaneous mutation of Dock7 results in lower trabecular bone mass and impaired periosteal expansion in aged female Misty mice. Bone, 2017, 105, 103-114.	1.4	15
110	Unsaturation level decreased in bone marrow fat of postmenopausal women with low bone density using high resolution magic angle spinning (HRMAS) 1H NMR spectroscopy. Bone, 2017, 105, 87-92.	1.4	26
111	Bone marrow adipocytes. Adipocyte, 2017, 6, 193-204.	1.3	151
112	Romosozumab — Promising or Practice Changing?. New England Journal of Medicine, 2017, 377, 1479-1480.	13.9	26
113	Contemporaneous reproduction of preclinical science: a case study of FSH and fat. Annals of the New York Academy of Sciences, 2017, 1404, 17-19.	1.8	12
114	New Insights into Fuel Choices of Nephron Progenitor Cells. Journal of the American Society of Nephrology: JASN, 2017, 28, 3133-3135.	3.0	3
115	A novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice. Bone, 2017, 103, 168-176.	1.4	38
116	Metformin Affects Cortical Bone Mass and Marrow Adiposity in Diet-Induced Obesity in Male Mice. Endocrinology, 2017, 158, 3369-3385.	1.4	54
117	Intracellular lipid droplets support osteoblast function. Adipocyte, 2017, 6, 250-258.	1.3	36
118	Energy Metabolism of Bone. Toxicologic Pathology, 2017, 45, 887-893.	0.9	34
119	The Determinants of Peak Bone Mass. Journal of Pediatrics, 2017, 180, 261-269.	0.9	147
120	The Central Nervous System and Bone Metabolism: An Evolving Story. Calcified Tissue International, 2017, 100, 476-485.	1.5	81
121	Real-Time H2O2Measurements in Bone Marrow Mesenchymal Stem Cells (MSCs) Show Increased Antioxidant Capacity in Cells From Osteoporotic Women. Journal of Cellular Biochemistry, 2017, 118, 585-593.	1.2	9
122	Structure and Function of Bone Marrow Adipocytes. , 2017, 8, 315-349.		22
123	Cover Image, Volume 232, Number 12, December 2017. Journal of Cellular Physiology, 2017, 232, i.	2.0	0
124	Bone and Energy Metabolism. Molecular and Integrative Toxicology, 2017, , 445-463.	0.5	1
125	Osteoporosis and Bone Biology. , 2016, , 1323-1364.		7
126	Qualitative Aspects of Bone Marrow Adiposity in Osteoporosis. Frontiers in Endocrinology, 2016, 7, 139.	1.5	34

#	Article	IF	CITATIONS
127	Reassessment of Adult Recommendations and Supplements of Calcium. Nutrition Today, 2016, 51, 25-28.	0.6	2
128	IRS-1 Functions as a Molecular Scaffold to Coordinate IGF-I/IGFBP-2 Signaling During Osteoblast Differentiation. Journal of Bone and Mineral Research, 2016, 31, 1300-1314.	3.1	25
129	Characterization of Fatty Acid Composition in Bone Marrow Fluid From Postmenopausal Women: Modification After Hip Fracture. Journal of Cellular Biochemistry, 2016, 117, 2370-2376.	1.2	30
130	Abdominal adipose tissue in MGUS and multiple myeloma. Skeletal Radiology, 2016, 45, 1277-1283.	1.2	24
131	Lipid Profiling of In Vitro Cell Models of Adipogenic Differentiation: Relationships With Mouse Adipose Tissues. Journal of Cellular Biochemistry, 2016, 117, 2182-2193.	1.2	34
132	Postmenopausal Osteoporosis. New England Journal of Medicine, 2016, 374, 2095-2097.	13.9	105
133	Building Better Bones with Biologics — A New Approach to Osteoporosis?. New England Journal of Medicine, 2016, 375, 1583-1584.	13.9	9
134	Network Analysis Implicates Alpha-Synuclein (Snca) in the Regulation of Ovariectomy-Induced Bone Loss. Scientific Reports, 2016, 6, 29475.	1.6	17
135	Tissue-engineered 3D cancer-in-bone modeling: silk and PUR protocols. BoneKEy Reports, 2016, 5, 842.	2.7	16
136	Vitamin D Deficiency — Is There Really a Pandemic?. New England Journal of Medicine, 2016, 375, 1817-1820.	13.9	236
137	Regulation of Glucose Handling by the Skeleton: Insights From Mouse and Human Studies. Diabetes, 2016, 65, 3225-3232.	0.3	56
138	Cardiac and Renovascular Complications in Type 2 Diabetes — Is There Hope?. New England Journal of Medicine, 2016, 375, 380-382.	13.9	33
139	Postmenopausal Osteoporosis. New England Journal of Medicine, 2016, 374, 254-262.	13.9	1,101
140	DMPâ€1 â€mediated <i>Ghr</i> gene recombination compromises skeletal development and impairs skeletal response to intermittent PTH. FASEB Journal, 2016, 30, 635-652.	0.2	24
141	Bone marrow adipose tissue: formation, function and regulation. Current Opinion in Pharmacology, 2016, 28, 50-56.	1.7	60
142	IGF-I and IGFBP-2 Stimulate AMPK Activation and Autophagy, Which Are Required for Osteoblast Differentiation. Endocrinology, 2016, 157, 268-281.	1.4	82
143	Navigating the bone marrow niche: translational insights and cancer-driven dysfunction. Nature Reviews Rheumatology, 2016, 12, 154-168.	3.5	108
144	Type 2 diabetes and the skeleton: new insights into sweet bones. Lancet Diabetes and Endocrinology,the, 2016, 4, 159-173.	5.5	179

#	Article	IF	CITATIONS
145	Skeletal integration of energy homeostasis: Translational implications. Bone, 2016, 82, 35-41.	1.4	13
146	Multiple Myeloma Progression: Dependence on Bone Marrow Adipose Tissue. Blood, 2016, 128, 3262-3262.	0.6	2
147	Obstructive Sleep Apnea and Metabolic Bone Disease: Insights Into the Relationship Between Bone and Sleep. Journal of Bone and Mineral Research, 2015, 30, 199-211.	3.1	73
148	Energy Excess, Glucose Utilization, and Skeletal Remodeling: New Insights. Journal of Bone and Mineral Research, 2015, 30, 1356-1361.	3.1	37
149	A phase I feasibility study of multi-modality imaging assessing rapid expansion of marrow fat and decreased bone mineral density in cancer patients. Bone, 2015, 73, 90-97.	1.4	27
150	A High Fat Diet Increases Bone Marrow Adipose Tissue (MAT) But Does Not Alter Trabecular or Cortical Bone Mass in C57BL/6J Mice. Journal of Cellular Physiology, 2015, 230, 2032-2037.	2.0	137
151	Adipose Tissue-Residing Progenitors (Adipocyte Lineage Progenitors and Adipose-Derived Stem Cells) Tj ETQq1 1	0.784314 0.8	rgBT /Overld
152	Serum FGF-21 levels are associated with worsened radial trabecular bone microarchitecture and decreased radial bone strength in women with anorexia nervosa. Bone, 2015, 77, 6-11.	1.4	41
153	Racial differences in bone loss and relation to menopause among HIV-infected and uninfected women. Bone, 2015, 77, 24-30.	1.4	10
154	Dynamic interplay between bone and multiple myeloma: Emerging roles of the osteoblast. Bone, 2015, 75, 161-169.	1.4	55
155	The effect of burn on serum concentrations of sclerostin and FGF23. Burns, 2015, 41, 1532-1535.	1.1	15
156	Propranolol Attenuates Risperidone-Induced Trabecular Bone Loss in Female Mice. Endocrinology, 2015, 156, 2374-2383.	1.4	35
157	Unraveling the Function of <i>FTO</i> Variants. New England Journal of Medicine, 2015, 373, 964-965.	13.9	9
158	lgfbp2 Deletion in Ovariectomized Mice Enhances Energy Expenditure but Accelerates Bone Loss. Endocrinology, 2015, 156, 4129-4140.	1.4	24
159	Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues. Nature Communications, 2015, 6, 7808.	5.8	332
160	The past 10 years—new hormones, new functions, new endocrine organs. Nature Reviews Endocrinology, 2015, 11, 681-686.	4.3	12
161	Cardiovascular Risk and Sodium–Glucose Cotransporter 2 Inhibition in Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 2178-2179.	13.9	13
162	The bone–fat interface: basic and clinical implications of marrow adiposity. Lancet Diabetes and Endocrinology,the, 2015, 3, 141-147.	5.5	198

#	Article	IF	CITATIONS
163	Anti-Sclerostin Treatment Prevents Multiple Myeloma Induced Bone Loss and Reduces Tumor Burden. Blood, 2015, 126, 119-119.	0.6	14
164	FGF-21 and Skeletal Remodeling During and After Lactation in C57BL/6J Mice. Endocrinology, 2014, 155, 3516-3526.	1.4	56
165	Inducible Models of Bone Loss. Current Protocols in Mouse Biology, 2014, 4, 165-180.	1.2	3
166	Bioenergetics During Calvarial Osteoblast Differentiation Reflect Strain Differences in Bone Mass. Endocrinology, 2014, 155, 1589-1595.	1.4	131
167	Circulating Sclerostin Associated With Vertebral Bone Marrow Fat in Older Men But Not Women. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2584-E2590.	1.8	51
168	Priscilla Chen 1944–2013. Journal of Bone and Mineral Research, 2014, 29, 517-517.	3.1	0
169	What's the matter with MAT? Marrow adipose tissue, metabolism, and skeletal health. Annals of the New York Academy of Sciences, 2014, 1311, 14-30.	1.8	193
170	Deficiency of Sef Is Associated With Increased Postnatal Cortical Bone Mass by Regulating Runx2 Activity. Journal of Bone and Mineral Research, 2014, 29, 1217-1231.	3.1	14
171	Use of Osmium Tetroxide Staining with Microcomputerized Tomography to Visualize and Quantify Bone Marrow Adipose Tissue In Vivo. Methods in Enzymology, 2014, 537, 123-139.	0.4	136
172	A Dual-Radioisotope Hybrid Whole-Body Micro-Positron Emission Tomography/Computed Tomography System Reveals Functional Heterogeneity and Early Local and Systemic Changes Following Targeted Radiation to the Murine Caudal Skeleton. Calcified Tissue International, 2014, 94, 544-552.	1.5	13
173	Effects of growth hormone administration for 6months on bone turnover and bone marrow fat in obese premenopausal women. Bone, 2014, 62, 29-35.	1.4	30
174	Vitamin D supplementation: bones of contention. Lancet, The, 2014, 383, 108-110.	6.3	9
175	Rationale and Design of the Vitamin D and Type 2 Diabetes (D2d) Study: A Diabetes Prevention Trial. Diabetes Care, 2014, 37, 3227-3234.	4.3	77
176	Diet and gene interactions influence the skeletal response to polyunsaturated fatty acids. Bone, 2014, 68, 100-107.	1.4	25
177	Marrow fat composition in anorexia nervosa. Bone, 2014, 66, 199-204.	1.4	90
178	Retinaldehyde dehydrogenase 1 deficiency inhibits PPARÎ ³ -mediated bone loss and marrow adiposity. Bone, 2014, 67, 281-291.	1.4	8
179	Bone Marrow Adipose Tissue Is an Endocrine Organ that Contributes to Increased Circulating Adiponectin during Caloric Restriction. Cell Metabolism, 2014, 20, 368-375.	7.2	415
180	Positive effects of brown adipose tissue on femoral bone structure. Bone, 2014, 58, 55-58.	1.4	40

#	Article	IF	CITATIONS
181	Vitamin D supplementation and fall risk. Lancet Diabetes and Endocrinology,the, 2014, 2, 532-534.	5.5	3
182	IGFBP-2 Directly Stimulates Osteoblast Differentiation. Journal of Bone and Mineral Research, 2014, 29, 2427-2438.	3.1	48
183	Bicc1 is a genetic determinant of osteoblastogenesis and bone mineral density. Journal of Clinical Investigation, 2014, 124, 2736-2749.	3.9	51
184	Bone and Fat. , 2013, , 963-976.		0
185	Serum IGF-1 Is Insufficient to Restore Skeletal Size in the Total Absence of the Growth Hormone Receptor. Journal of Bone and Mineral Research, 2013, 28, 1575-1586.	3.1	28
186	Canonical Nlrp3 Inflammasome Links Systemic Low-Grade Inflammation to Functional Decline in Aging. Cell Metabolism, 2013, 18, 519-532.	7.2	494
187	Single cell gene expression profiling of cortical osteoblast lineage cells. Bone, 2013, 53, 174-181.	1.4	8
188	IGFBP-2 is a negative predictor of cold-induced brown fat and bone mineral density in young non-obese women. Bone, 2013, 53, 336-339.	1.4	25
189	Marrow Fat and Bone—New Perspectives. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 935-945.	1.8	319
190	Inducible Brown Adipose Tissue, or Beige Fat, Is Anabolic for the Skeleton. Endocrinology, 2013, 154, 2687-2701.	1.4	109
191	Common misconceptions about vitamin D—implications for clinicians. Nature Reviews Endocrinology, 2013, 9, 434-438.	4.3	31
192	Vertebral Bone Marrow Fat Associated With Lower Trabecular BMD and Prevalent Vertebral Fracture in Older Adults. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2294-2300.	1.8	199
193	Abdominal Fat Is Associated With Lower Bone Formation and Inferior Bone Quality in Healthy Premenopausal Women: A Transiliac Bone Biopsy Study. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2562-2572.	1.8	165
194	Vitamin D and Calcium. Clinical Obstetrics and Gynecology, 2013, 56, 654-658.	0.6	2
195	Inhibition of Prefâ€1 (preadipocyte factor 1) by oestradiol in adolescent girls with anorexia nervosa is associated with improvement in lumbar bone mineral density. Clinical Endocrinology, 2013, 79, 326-332.	1.2	30
196	Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell, 2013, 12, 851-862.	3.0	258
197	Altered thermogenesis and impaired bone remodeling in <i>Misty</i> mice. Journal of Bone and Mineral Research, 2013, 28, 1885-1897.	3.1	57
198	The Transcription Factor Paired-Related Homeobox 1 (Prrx1) Inhibits Adipogenesis by Activating Transforming Growth Factor-l² (TGFl²) Signaling. Journal of Biological Chemistry, 2013, 288, 3036-3047.	1.6	56

#	Article	IF	CITATIONS
199	Bone Remodeling and Energy Metabolism: New Perspectives. Bone Research, 2013, 1, 72-84.	5.4	54
200	Deficiency of Retinaldehyde Dehydrogenase 1 Induces BMP2 and Increases Bone Mass In Vivo. PLoS ONE, 2013, 8, e71307.	1.1	23
201	Bone Marrow Oxytocin Mediates the Anabolic Action of Estrogen on the Skeleton. Journal of Biological Chemistry, 2012, 287, 29159-29167.	1.6	66
202	Tissue-specific expression of Sprouty1 in mice protects against high-fat diet-induced fat accumulation, bone loss and metabolic dysfunction. British Journal of Nutrition, 2012, 108, 1025-1033.	1.2	14
203	A High-Fat Diet Induces Bone Loss in Mice Lacking the Alox5 Gene. Endocrinology, 2012, 153, 6-16.	1.4	20
204	Young Women with Cold-Activated Brown Adipose Tissue Have Higher Bone Mineral Density and Lower Pref-1 than Women without Brown Adipose Tissue: A Study in Women with Anorexia Nervosa, Women Recovered from Anorexia Nervosa, and Normal-Weight Women. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E584-E590.	1.8	94
205	Following the Bone Density Trail: A Clinical Perspective. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1176-1178.	1.8	13
206	Blocking antibody to the β-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14574-14579.	3.3	129
207	Building bones by knocking down genes. Nature Medicine, 2012, 18, 202-204.	15.2	9
208	Insulin-Like Growth Factor (IGF) Binding Protein 2 Functions Coordinately with Receptor Protein Tyrosine Phosphatase β and the IGF-I Receptor To Regulate IGF-I-Stimulated Signaling. Molecular and Cellular Biology, 2012, 32, 4116-4130.	1.1	73
209	Insulin-like Growth Factor Binding Protein-4 Differentially Inhibits Growth Factor-induced Angiogenesis. Journal of Biological Chemistry, 2012, 287, 1779-1789.	1.6	35
210	The Skeleton and the Sympathetic Nervous System: It's about Time!. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3908-3911.	1.8	11
211	The Insulin-Like Growth Factor System in Bone. Endocrinology and Metabolism Clinics of North America, 2012, 41, 323-333.	1.2	84
212	Continuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long?. New England Journal of Medicine, 2012, 366, 2051-2053.	13.9	249
213	Vitamin D safety and requirements. Archives of Biochemistry and Biophysics, 2012, 523, 64-72.	1.4	46
214	Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain. Bone, 2012, 50, 490-498.	1.4	37
215	N-cadherin adherens junctions mediate osteogenesis through PI3K signaling. Bone, 2012, 50, 54-62.	1.4	44
216	Altered plasma membrane dynamics of bone morphogenetic protein receptor type Ia in a low bone mass mouse model. Bone, 2012, 50, 189-199.	1.4	23

#	Article	IF	CITATIONS
217	Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls. Bone, 2012, 51, 474-479.	1.4	39
218	Bone-Derived IGF Mediates Crosstalk between Bone and Breast Cancer Cells in Bony Metastases. Cancer Research, 2012, 72, 4238-4249.	0.4	75
219	Marrow fat and preadipocyte factor-1 levels decrease with recovery in women with anorexia nervosa. Journal of Bone and Mineral Research, 2012, 27, 1864-1871.	3.1	98
220	Understanding leptin-dependent regulation of skeletal homeostasis. Biochimie, 2012, 94, 2089-2096.	1.3	77
221	In Osteoporosis, differentiation of mesenchymal stem cells (MSCs) improves bone marrow adipogenesis. Biological Research, 2012, 45, 279-287.	1.5	157
222	IOM Committee Members Respond to Endocrine Society Vitamin D Guideline. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1146-1152.	1.8	492
223	Bone morphogenetic protein receptor type la localization causes increased BMP2 signaling in mice exhibiting increased peak bone mass phenotype. Journal of Cellular Physiology, 2012, 227, 2870-2879.	2.0	13
224	Increase in circulating levels of IGFâ€1 and IGFâ€1/IGFBPâ€3 molar ratio over a decade is associated with colorectal adenomatous polyps. International Journal of Cancer, 2012, 131, 512-517.	2.3	43
225	Insulin-like growth factor-binding protein-2 is required for osteoclast differentiation. Journal of Bone and Mineral Research, 2012, 27, 390-400.	3.1	38
226	The Nonskeletal Effects of Vitamin D: An Endocrine Society Scientific Statement. Endocrine Reviews, 2012, 33, 456-492.	8.9	611
227	Bone As An Endocrine Organ. Endocrine Practice, 2012, 18, 758-762.	1.1	106
228	Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nature Medicine, 2012, 18, 1095-1101.	15.2	498
229	The effect of gonadal and adrenal steroid therapy on skeletal health in adolescents and young women with anorexia nervosa. Metabolism: Clinical and Experimental, 2012, 61, 1010-1020.	1.5	83
230	Multiple quantitative trait loci for cortical and trabecular bone regulation map to mid-distal mouse chromosome 4 that shares linkage homology to human chromosome 1p36. Journal of Bone and Mineral Research, 2012, 27, 47-57.	3.1	9
231	Diseases of Energy and Lipid Metabolism and Bone: Emerging Therapeutics. , 2012, , 133-146.		0
232	The 2011 IOM Report on Vitamin D and Calcium Requirements for North America: Clinical Implications for Providers Treating Patients With Low Bone Mineral Density. Journal of Clinical Densitometry, 2011, 14, 79-84.	0.5	78
233	Vitamin D Insufficiency. New England Journal of Medicine, 2011, 364, 248-254.	13.9	727
234	The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 53-58.	1.8	3,343

#	Article	IF	CITATIONS
235	Determinants of bone mineral density in obese premenopausal women. Bone, 2011, 48, 748-754.	1.4	144
236	Selective osteoblast overexpression of IGF-I in mice prevents low protein-induced deterioration of bone strength and material level properties. Bone, 2011, 49, 1073-1079.	1.4	18
237	Investigating the mechanism for maintaining eucalcemia despite immobility and anuria in the hibernating American black bear (Ursus americanus). Bone, 2011, 49, 1205-1212.	1.4	35
238	Emerging therapeutic opportunities for skeletal restoration. Nature Reviews Drug Discovery, 2011, 10, 141-156.	21.5	125
239	Increased serum IGF-1 levels protect the musculoskeletal system but are associated with elevated oxidative stress markers and increased mortality independent of tissue igf1 gene expression. Aging Cell, 2011, 10, 547-550.	3.0	27
240	Vertebral Bone Marrow Fat Is Positively Associated With Visceral Fat and Inversely Associated With IGFâ€l in Obese Women. Obesity, 2011, 19, 49-53.	1.5	268
241	An essential role for the circadianâ€regulated gene Nocturnin in osteogenesis: the importance of local timebogning in skeletal homeostasis Annals of the New York Academy of Sciences, 2011, 1237, 58-63.	1.8	37
0.40	KnowâźâźThis article is a summary of the Institute of Medicine report entitled Dietary Reference Intakes for Calcium and Vitamin D (available at) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 Td (http://www.iom.edu/Repo	rts/2010/I	Dietary-Refere

#	Article	IF	CITATIONS
253	Vitamin D and falls—are intermittent, high doses better?. Nature Reviews Endocrinology, 2011, 7, 695-696.	4.3	4
254	Change in Undercarboxylated Osteocalcin Is Associated with Changes in Body Weight, Fat Mass, and Adiponectin: Parathyroid Hormone (1-84) or Alendronate Therapy in Postmenopausal Women with Osteoporosis (the PaTH Study). Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1982-E1989.	1.8	95
255	Serum IGF-1 Affects Skeletal Acquisition in a Temporal and Compartment-Specific Manner. PLoS ONE, 2011, 6, e14762.	1.1	42
256	Vitamin D and Fat. , 2011, , 769-776.		1
257	Bone Marrow and Stem Cell Recruitment. , 2011, , .		1
258	Temperatures rising: brown fat and bone. Discovery Medicine, 2011, 11, 179-85.	0.5	26
259	Growth hormone regulates the balance between bone formation and bone marrow adiposity. Journal of Bone and Mineral Research, 2010, 25, 757-768.	3.1	107
260	Growth hormone protects against ovariectomy-induced bone loss in states of low circulating insulin-like growth factor (IGF-1). Journal of Bone and Mineral Research, 2010, 25, 235-246.	3.1	26
261	Bone marrow changes in adolescent girls with anorexia nervosa. Journal of Bone and Mineral Research, 2010, 25, 298-304.	3.1	130
262	Elevated serum IGF-1 levels synergize PTH action on the skeleton only when the tissue IGF-1 axis is intact. Journal of Bone and Mineral Research, 2010, 25, 2051-2058.	3.1	38
263	Elevated serum levels of IGF-1 are sufficient to establish normal body size and skeletal properties even in the absence of tissue IGF-1. Journal of Bone and Mineral Research, 2010, 25, 1257-1266.	3.1	64
264	Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. Journal of Bone and Mineral Research, 2010, 25, 2078-2088.	3.1	295
265	Exploiting new targets for old bones. Journal of Bone and Mineral Research, 2010, 25, 934-936.	3.1	3
266	Sex-specific regulation of body size and bone slenderness by the acid labile subunit. Journal of Bone and Mineral Research, 2010, 25, 2059-2068.	3.1	31
267	The IGFâ€I regulatory system and its impact on skeletal and energy homeostasis. Journal of Cellular Biochemistry, 2010, 111, 14-19.	1.2	54
268	Novel insights into the relationship between diabetes and osteoporosis. Diabetes/Metabolism Research and Reviews, 2010, 26, 622-630.	1.7	106
269	Nocturnin: a circadian target of Ppargâ€induced adipogenesis. Annals of the New York Academy of Sciences, 2010, 1192, 131-138.	1.8	25
270	Obesity, diabetes mellitus and last but not least, osteoporosis. Arquivos Brasileiros De Endocrinologia E Metabologia, 2010, 54, 150-157.	1.3	40

#	Article	IF	CITATIONS
271	Revisiting the Rosiglitazone Story — Lessons Learned. New England Journal of Medicine, 2010, 363, 803-806.	13.9	117
272	The Insulin-like Growth Factor-1 Binding Protein Acid-labile Subunit Alters Mesenchymal Stromal Cell Fate. Journal of Biological Chemistry, 2010, 285, 4709-4714.	1.6	20
273	A circadian-regulated gene, <i>Nocturnin</i> , promotes adipogenesis by stimulating PPAR-γ nuclear translocation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10508-10513.	3.3	136
274	Visceral Fat Is a Negative Predictor of Bone Density Measures in Obese Adolescent Girls. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1247-1255.	1.8	217
275	The many facets of PPARÎ ³ : novel insights for the skeleton. American Journal of Physiology - Endocrinology and Metabolism, 2010, 299, E3-E9.	1.8	56
276	Skeletal aging and the adipocyte program. Cell Cycle, 2010, 9, 3672-3678.	1.3	50
277	A novel spontaneous mutation of Irs1 in mice results in hyperinsulinemia, reduced growth, low bone mass and impaired adipogenesis. Journal of Endocrinology, 2010, 204, 241-253.	1.2	29
278	Placebo-Controlled Trials in Osteoporosis — Proceeding with Caution. New England Journal of Medicine, 2010, 363, 1365-1367.	13.9	18
279	Adiposity and bone accrual—still an established paradigm?. Nature Reviews Endocrinology, 2010, 6, 63-64.	4.3	22
280	Minireview: A Skeleton in Serotonin's Closet?. Endocrinology, 2010, 151, 4103-4108.	1.4	28
281	Frailty: A D-Ficiency Syndrome of Aging?. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5210-5212.	1.8	13
282	Developing drugs to treat osteoporosis: lessons learned?. Expert Opinion on Pharmacotherapy, 2010, 11, 867-869.	0.9	6
283	Preadipocyte Factor-1 Is Associated with Marrow Adiposity and Bone Mineral Density in Women with Anorexia Nervosa. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 407-413.	1.8	87
284	Sprouty1 is a critical regulatory switch of mesenchymal stem cell lineage allocation. FASEB Journal, 2010, 24, 3264-3273.	0.2	53
285	Effects of alcohol on skeletal response to growth hormone in hypophysectomized rats. Bone, 2010, 46, 806-812.	1.4	18
286	No Bones About It: Insulin Modulates Skeletal Remodeling. Cell, 2010, 142, 198-200.	13.5	32
287	PPARÎ ³ : a circadian transcription factor in adipogenesis and osteogenesis. Nature Reviews Endocrinology, 2010, 6, 629-636.	4.3	277
288	Placebo-Controlled Fracture Trials in Osteoporosis — Comment on the Article by Stein and Ray. New England Journal of Medicine, 2010, 363, e21.	13.9	3

#	Article	IF	CITATIONS
289	Fat targets for skeletal health. Nature Reviews Rheumatology, 2009, 5, 365-372.	3.5	124
290	Serum complexes of insulinâ€like growth factorâ€1 modulate skeletal integrity and carbohydrate metabolism. FASEB Journal, 2009, 23, 709-719.	0.2	90
291	Serotonin, leptin and the central control of bone remodeling. Nature Reviews Rheumatology, 2009, 5, 657-658.	3.5	11
292	Skeletal Consequences of Deletion of Steroid Receptor Coactivator-2/Transcription Intermediary Factor-2. Journal of Biological Chemistry, 2009, 284, 18767-18777.	1.6	21
293	Supplements of 20 μg/d Cholecalciferol Optimized Serum 25-Hydroxyvitamin D Concentrations in 80% of Premenopausal Women in Winter. Journal of Nutrition, 2009, 139, 540-546.	1.3	50
294	The future of mouse genetics in osteoporosis research. IBMS BoneKEy, 2009, 6, 200-209.	0.1	3
295	Increased Bone Marrow Fat in Anorexia Nervosa. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2129-2136.	1.8	332
296	Strain-Specific Effects of Rosiglitazone on Bone Mass, Body Composition, and Serum Insulin-Like Growth Factor-I. Endocrinology, 2009, 150, 1330-1340.	1.4	77
297	Response to Dr. Sempos and Dr. Picciano. Journal of Nutrition, 2009, 139, 1205-1206.	1.3	0
298	PPARÎ ³ 2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. Journal of Cellular Biochemistry, 2009, 106, 232-246.	1.2	156
299	Insulin-like growth factor-I and bone: lessons from mice and men. Pediatric Nephrology, 2009, 24, 1277-1285.	0.9	49
300	Marrow Fat and Bone: New Insights from Mice and Humans. Clinical Reviews in Bone and Mineral Metabolism, 2009, 7, 216-223.	1.3	3
301	Bone loss or lost bone: Rationale and recommendations for the diagnosis and treatment of early postmenopausal bone loss. Current Osteoporosis Reports, 2009, 7, 118-126.	1.5	49
302	Breaking into bone biology: serotonin's secrets. Nature Medicine, 2009, 15, 145-146.	15.2	22
303	Serum Insulinâ€Like Growth Factorâ€1 Binding Proteins 1 and 2 and Mortality in Older Adults: The Health, Aging, and Body Composition Study. Journal of the American Geriatrics Society, 2009, 57, 1213-1218.	1.3	63
304	Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. Aging Cell, 2009, 8, 277-287.	3.0	359
305	Mechanical Stimulation of Mesenchymal Stem Cell Proliferation and Differentiation Promotes Osteogenesis While Preventing Dietary-Induced Obesity. Journal of Bone and Mineral Research, 2009, 24, 50-61.	3.1	232
306	Serum IGF-1 Determines Skeletal Strength by Regulating Subperiosteal Expansion and Trait Interactions. Journal of Bone and Mineral Research, 2009, 24, 1481-1492.	3.1	93

#	Article	IF	CITATIONS
307	Leptin's RIGHT Turn to the Brain Stem. Cell Metabolism, 2009, 10, 243-244.	7.2	5
308	Bone, Fat, and Body Composition: Evolving Concepts in the Pathogenesis of Osteoporosis. American Journal of Medicine, 2009, 122, 409-414.	0.6	189
309	Serotonin Rising — The Bone, Brain, Bowel Connection. New England Journal of Medicine, 2009, 360, 957-959.	13.9	50
310	Marrow Fat and the Bone Microenvironment: Developmental, Functional, and Pathological Implications. Critical Reviews in Eukaryotic Gene Expression, 2009, 19, 109-124.	0.4	304
311	Questioning the Accuracy of a Recent Review of Osteoporosis Medications. Annals of Internal Medicine, 2009, 150, 423.	2.0	0
312	Impact of Pregnancy-Associated Plasma Protein-A Deletion on the Adult Murine Skeleton. Journal of Bone and Mineral Research, 2008, 23, 655-662.	3.1	34
313	Effects of PTH and Alendronate on Type I Collagen Isomerization in Postmenopausal Women With Osteoporosis: The PaTH Study. Journal of Bone and Mineral Research, 2008, 23, 1442-1448.	3.1	28
314	Quantitative Trait Loci for BMD in an SM/J by NZB/BINJ Intercross Population and Identification of <i>Trps1</i> as a Probable Candidate Gene. Journal of Bone and Mineral Research, 2008, 23, 1529-1537.	3.1	27
315	<i>PPARG</i> by Dietary Fat Interaction Influences Bone Mass in Mice and Humans. Journal of Bone and Mineral Research, 2008, 23, 1398-1408.	3.1	56
316	Sugar and Bone: A Not-So Sweet Story. Journal of Bone and Mineral Research, 2008, 23, 1881-1883.	3.1	11
317	Bone Remodeling, Energy Metabolism, and the Molecular Clock. Cell Metabolism, 2008, 7, 7-10.	7.2	92
318	Dual-Energy X-Ray Absorptiometry Technical Issues: The 2007 ISCD Official Positions. Journal of Clinical Densitometry, 2008, 11, 109-122.	0.5	48
319	Randomized Trial of Once-Weekly Parathyroid Hormone (1-84) on Bone Mineral Density and Remodeling. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2166-2172.	1.8	48
320	Circulating IGF-I and bone remodeling: New insights into old questions. IBMS BoneKEy, 2008, 5, 7-15.	0.1	1
321	The Rosiglitazone Story — Lessons from an FDA Advisory Committee Meeting. New England Journal of Medicine, 2007, 357, 844-846.	13.9	199
322	Is risedronate or alendronate more effective at preventing nonvertebral fractures in women with osteoporosis?. Nature Clinical Practice Rheumatology, 2007, 3, 378-379.	3.2	5
323	Effects of parathyroid hormone (1–34) on tibia in an adult rat model for chronic alcohol abuse. Bone, 2007, 40, 1013-1020.	1.4	28
324	Impact of seafood and fruit consumption on bone mineral density. Maturitas, 2007, 56, 1-11.	1.0	87

#	Article	IF	CITATIONS
325	Insulin-like growth factor I stimulates recovery of bone lost after a period of skeletal unloading. Journal of Applied Physiology, 2007, 103, 125-131.	1.2	21
326	A Chromosomal Inversion within a Quantitative Trait Locus Has a Major Effect on Adipogenesis and Osteoblastogenesis. Annals of the New York Academy of Sciences, 2007, 1116, 291-305.	1.8	11
327	Genetic Dissection of Mouse Distal Chromosome 1 Reveals Three Linked BMD QTLs With Sex-Dependent Regulation of Bone Phenotypes. Journal of Bone and Mineral Research, 2007, 22, 1187-1196.	3.1	50
328	Aging Impairs IGF-I Receptor Activation and Induces Skeletal Resistance to IGF-I. Journal of Bone and Mineral Research, 2007, 22, 1271-1279.	3.1	68
329	Adherence to Bisphosphonate Therapy and Fracture Rates in Osteoporotic Women: Relationship to Vertebral and Nonvertebral Fractures From 2 US Claims Databases. Mayo Clinic Proceedings, 2006, 81, 1013-1022.	1.4	652
330	Mechanisms of Disease: is osteoporosis the obesity of bone?. Nature Clinical Practice Rheumatology, 2006, 2, 35-43.	3.2	810
331	Alendronate with and without cholecalciferol for osteoporosis: results of a 15â€week randomized controlled trial. Current Medical Research and Opinion, 2006, 22, 1745-1755.	0.9	28
332	Postnatal growth and bone mass in mice with IGF-I haploinsufficiency. Bone, 2006, 38, 826-835.	1.4	72
333	Transgenic mice with osteoblast-targeted insulin-like growth factor-I show increased bone remodeling. Bone, 2006, 39, 494-504.	1.4	90
334	Chromosomal inversion discovered in C3H/HeJ mice. Genomics, 2006, 87, 311-313.	1.3	16
335	The Genetics of PPARG and the Skeleton. PPAR Research, 2006, 2006, 1-8.	1.1	12
336	IGF-I secretion by prostate carcinoma cells does not alter tumor-bone cell interactions in vitro or in vivo. Prostate, 2006, 66, 789-800.	1.2	18
337	Safety and Efficacy of Teriparatide in Elderly Women with Established Osteoporosis: Bone Anabolic Therapy from a Geriatric Perspective. Journal of the American Geriatrics Society, 2006, 54, 782-789.	1.3	122
338	REPLY BY BOONEN ET AL Journal of the American Geriatrics Society, 2006, 54, 1961-1962.	1.3	1
339	Nuclear Receptor Coactivator-3 Alleles Are Associated with Serum Bioavailable Testosterone, Insulin-Like Growth Factor-1, and Vertebral Bone Mass in Men. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 307-312.	1.8	12
340	The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. Journal of Endocrinology, 2006, 189, 289-299.	1.2	78
341	Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study. Journal of Bone and Mineral Research, 2005, 20, 141-151.	3.1	291
342	How to Interpret Surrogate Markers of Efficacy in Osteoporosis. Journal of Bone and Mineral Research, 2005, 20, 1263-1264.	3.1	0

#	Article	IF	CITATIONS
343	Ovariectomy-Induced Bone Loss Varies Among Inbred Strains of Mice. Journal of Bone and Mineral Research, 2005, 20, 1085-1092.	3.1	227
344	Spontaneous Fractures in the Mouse Mutant sfx Are Caused by Deletion of the Gulonolactone Oxidase Gene, Causing Vitamin C Deficiency. Journal of Bone and Mineral Research, 2005, 20, 1597-1610.	3.1	55
345	Continuous PTH and PTHrP Infusion Causes Suppression of Bone Formation and Discordant Effects on 1,25(OH)2Vitamin D. Journal of Bone and Mineral Research, 2005, 20, 1792-1803.	3.1	124
346	Skeletal Effects of Estrogen Are Mediated by Opposing Actions of Classical and Nonclassical Estrogen Receptor Pathways. Journal of Bone and Mineral Research, 2005, 20, 1992-2001.	3.1	66
347	Quantitative Trait Loci That Determine BMD in C57BL/6J and 129S1/SvImJ Inbred Mice. Journal of Bone and Mineral Research, 2005, 21, 105-112.	3.1	39
348	Adolescent Girls in Maine Are at Risk for Vitamin D Insufficiency. Journal of the American Dietetic Association, 2005, 105, 971-974.	1.3	197
349	Idiopathic osteoporosis in premenopausal women. Osteoporosis International, 2005, 16, 526-533.	1.3	43
350	Familial aggregation of bone mineral density and bone mineral content in a Chinese population. Osteoporosis International, 2005, 16, 1917-1923.	1.3	8
351	Serum insulin-like growth factor binding protein-1 levels and bone mineral density in older adults: The Rancho Bernardo Study. Osteoporosis International, 2005, 16, 1948-1954.	1.3	10
352	Allelic differences in a quantitative trait locus affecting insulin-like growth factor-I impact skeletal acquisition and body composition. Pediatric Nephrology, 2005, 20, 255-260.	0.9	26
353	The insulin-like growth factor-I gene and osteoporosis: A critical appraisal. Gene, 2005, 361, 38-56.	1.0	138
354	A rational approach to evidence gaps in the management of osteoporosis. American Journal of Medicine, 2005, 118, 1183-1189.	0.6	18
355	One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis. New England Journal of Medicine, 2005, 353, 555-565.	13.9	568
356	Postmenopausal Osteoporosis. New England Journal of Medicine, 2005, 353, 595-603.	13.9	268
357	Insulin-Like Growth Factor-1. Journal of the American Geriatrics Society, 2004, 52, 1962-1963.	1.3	19
358	Weekly Oral Alendronic Acid in Male Osteoporosis. Clinical Drug Investigation, 2004, 24, 333-341.	1.1	35
359	Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program. Bone, 2004, 35, 1046-1058.	1.4	101
360	What's new with PTH in osteoporosis: where are we and where are we headed?. Trends in Endocrinology and Metabolism, 2004, 15, 229-233.	3.1	42

#	Article	IF	CITATIONS
361	The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis. Obstetrical and Gynecological Survey, 2004, 59, 199-201.	0.2	22
362	Vignettes in Osteoporosis: A Road Map to Successful Therapeutics. Journal of Bone and Mineral Research, 2003, 19, 3-10.	3.1	7
363	Mapping Quantitative Trait Loci for Vertebral Trabecular Bone Volume Fraction and Microarchitecture in Mice. Journal of Bone and Mineral Research, 2003, 19, 587-599.	3.1	98
364	Genetic Effects for Femoral Biomechanics, Structure, and Density in C57BL/6J and C3H/HeJ Inbred Mouse Strains. Journal of Bone and Mineral Research, 2003, 18, 1758-1765.	3.1	68
365	Perturbations in Bone Formation and Resorption in Insulin-Like Growth Factor Binding Protein-3 Transgenic Mice. Journal of Bone and Mineral Research, 2003, 18, 1834-1841.	3.1	72
366	Congenic Strains of Mice for Verification and Genetic Decomposition of Quantitative Trait Loci for Femoral Bone Mineral Density. Journal of Bone and Mineral Research, 2003, 18, 175-185.	3.1	58
367	Paracrine Overexpression of IGFBP-4 in Osteoblasts of Transgenic Mice Decreases Bone Turnover and Causes Global Growth Retardation. Journal of Bone and Mineral Research, 2003, 18, 836-843.	3.1	85
368	A Missense Mutation in the Mouse Col2a1 Gene Causes Spondyloepiphyseal Dysplasia Congenita, Hearing Loss, and Retinoschisis. Journal of Bone and Mineral Research, 2003, 18, 1612-1621.	3.1	61
369	Growth Hormone Rising: Did We Quit Too Quickly?. Journal of Bone and Mineral Research, 2003, 18, 406-409.	3.1	15
370	The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis. New England Journal of Medicine, 2003, 349, 1207-1215.	13.9	1,133
371	Severe Hypocalcemia after Intravenous Bisphosphonate Therapy in Occult Vitamin D Deficiency. New England Journal of Medicine, 2003, 348, 1503-1504.	13.9	158
372	From Mouse to Man: Redefining the Role of Insulin-Like Growth Factor-I in the Acquisition of Bone Mass. Experimental Biology and Medicine, 2003, 228, 245-252.	1.1	91
373	Effects of Oral Dehydroepiandrosterone on Bone Density in Young Women With Anorexia Nervosa: A Randomized Trial. Obstetrical and Gynecological Survey, 2003, 58, 256-258.	0.2	0
374	Osteoblast-specific Knockout of the Insulin-like Growth Factor (IGF) Receptor Gene Reveals an Essential Role of IGF Signaling in Bone Matrix Mineralization. Journal of Biological Chemistry, 2002, 277, 44005-44012.	1.6	621
375	Musculoskeletal Effects of the Recombinant Human IGF-I/IGF Binding Protein-3 Complex in Osteoporotic Patients with Proximal Femoral Fracture: A Double-Blind, Placebo-Controlled Pilot Study. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1593-1599.	1.8	108
376	Effects of Oral Dehydroepiandrosterone on Bone Density in Young Women with Anorexia Nervosa: A Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4935-4941.	1.8	224
377	Physiologic regulators of bone turnover in young women with anorexia nervosa. Journal of Pediatrics, 2002, 141, 64-70.	0.9	124
378	North American Male Reference Population for Speed of Sound in Bone at Multiple Skeletal Sites. Journal of Clinical Densitometry, 2002, 5, 63-71.	0.5	14

#	Article	IF	CITATIONS
379	Bone Density in Ambulatory and Immobile Children. Journal of Clinical Densitometry, 2002, 5, 327-334.	0.5	13
380	Gene expression between a congenic strain that contains a quantitative trait locus of high bone density from CAST/EiJ and its wild-type strain C57BL/6J. Functional and Integrative Genomics, 2002, 1, 375-386.	1.4	29
381	Generation of a New Congenic Mouse Strain to Test the Relationships Among Serum Insulin-like Growth Factor I, Bone Mineral Density, and Skeletal Morphology In Vivo. Journal of Bone and Mineral Research, 2002, 17, 570-579.	3.1	73
382	Insulin-Like Growth Factor I Is Required for the Anabolic Actions of Parathyroid Hormone on Mouse Bone. Journal of Bone and Mineral Research, 2002, 17, 1570-1578.	3.1	231
383	Circulating levels of IGF-1 directly regulate bone growth and density. Journal of Clinical Investigation, 2002, 110, 771-781.	3.9	640
384	Circulating levels of IGF-1 directly regulate bone growth and density. Journal of Clinical Investigation, 2002, 110, 771-781.	3.9	469
385	Add-backs to prevent skeletal fragility: foresight or folly?. Menopause, 2002, 9, 224-226.	0.8	0
386	Multisite Bone Ultrasound Measurement on North American Female Reference Population. Journal of Clinical Densitometry, 2001, 4, 239-248.	0.5	27
387	Emerging Anabolic Treatments for Osteoporosis. Rheumatic Disease Clinics of North America, 2001, 27, 215-233.	0.8	24
388	Growth Hormone Administration and Exercise Effects on Muscle Fiber Type and Diameter in Moderately Frail Older People. Journal of the American Geriatrics Society, 2001, 49, 852-858.	1.3	87
389	Insulin-like growth factor binding proteins in femoral and vertebral bone marrow stromal cells: Expression and regulation by thyroid hormone and dexamethasone. Journal of Cellular Biochemistry, 2001, 81, 229-240.	1.2	38
390	The Skeletal Structure of Insulin-Like Growth Factor I-Deficient Mice. Journal of Bone and Mineral Research, 2001, 16, 2320-2329.	3.1	175
391	Variation in Bone Biomechanical Properties, Microstructure, and Density in BXH Recombinant Inbred Mice. Journal of Bone and Mineral Research, 2001, 16, 206-213.	3.1	100
392	Treatment of postmenopausal osteoporosis: an evidence-based approach. , 2001, 2, 35-43.		7
393	Anabolic Therapy for Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 957-964.	1.8	187
394	Enhancement of Bone Mass in Osteoporotic Women with Parathyroid Hormone followed by Alendronate1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2129-2134.	1.8	271
395	Genetic Regulation of Cortical and Trabecular Bone Strength and Microstructure in Inbred Strains of Mice. Journal of Bone and Mineral Research, 2000, 15, 1126-1131.	3.1	181
396	Targeted Overexpression of Insulin-Like Growth Factor I to Osteoblasts of Transgenic Mice: Increased Trabecular Bone Volume without Increased Osteoblast Proliferation ¹ . Endocrinology, 2000, 141, 2674-2682.	1.4	323

#	Article	IF	CITATIONS
397	Support Group Intervention for Women with Osteoporosis. Rehabilitation Nursing, 2000, 25, 88-92.	0.3	9
398	Fluoride and fractures: an ecological fallacy. Lancet, The, 2000, 355, 247-248.	6.3	11
399	Osteoclast Formation in Bone Marrow Cultures from Two Inbred Strains of Mice with Different Bone Densities. Journal of Bone and Mineral Research, 1999, 14, 39-46.	3.1	54
400	Quantitative trait loci for bone density in C57BL/6J and CAST/EiJ inbred mice. Mammalian Genome, 1999, 10, 1043-1049.	1.0	153
401	A genome-wide scan for loci linked to forearm bone mineral density. Human Genetics, 1999, 104, 226-233.	1.8	131
402	Dietary Changes Favorably Affect Bone Remodeling in Older Adults. Journal of the American Dietetic Association, 1999, 99, 1228-1233.	1.3	213
403	Circulating IGF-I: New Perspectives for a New Century. Trends in Endocrinology and Metabolism, 1999, 10, 136-141.	3.1	128
404	Male Skeletal Health and Osteoporosis. Trends in Endocrinology and Metabolism, 1999, 10, 244-250.	3.1	18
405	Effect of short-term medroxyprogesterone acetate on left ventricular mass: Role of insulin-like growth factor-1. Metabolism: Clinical and Experimental, 1999, 48, 1328-1331.	1.5	5
406	Perspectives on Bone Mechanical Properties and Adaptive Response to Mechanical Challenge. Journal of Clinical Densitometry, 1999, 2, 423-433.	0.5	39
407	Images in Densitometry. Journal of Clinical Densitometry, 1999, 2, 55-57.	O.5	0
408	Perplexing Polymorphisms: D(i)ps, Sn(i)ps, and Trips. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4465-4466.	1.8	3
409	Pre-emptive bone strikes in prevention of osteoporosis. Lancet, The, 1998, 351, 927-928.	6.3	11
410	Peripheral Bone Mass Measurements. Journal of Clinical Densitometry, 1998, 1, 287-294.	0.5	10
411	Forearm Bone Mineral Density in Chinese Women. Journal of Clinical Densitometry, 1998, 1, 149-156.	O.5	4
412	An Editor-in-Chief's Note. Journal of Clinical Densitometry, 1998, 1, 3-4.	0.5	0
413	Pathogenesis and Treatment of Glucocorticoid-Induced Osteoporosis. Drugs and Aging, 1998, 12, 477-484.	1.3	30
414	Association Between Insulin-Like Growth Factor I and Bone Mineral Density in Older Women and Men: The Framingham Heart Study1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4257-4262.	1.8	209

#	Article	IF	CITATIONS
415	Lack of an Association Between Insulinâ€like Growth Factorâ€l and Body Composition, Muscle Strength, Physical Performance or Selfâ€Reported Mobility Among Older Persons with Functional Limitations. Journal of the American Geriatrics Society, 1998, 46, 822-828.	1.3	42
416	Insulin-like growth factor-I and parathyroid hormone: potential new therapeutic agents for the treatment of osteoporosis. Expert Opinion on Investigational Drugs, 1997, 6, 1193-1198.	1.9	2
417	Endocrine disorders and osteoporosis. Current Opinion in Rheumatology, 1997, 9, 355-361.	2.0	13
418	THE PATHOPHYSIOLOGY AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS. Endocrinology and Metabolism Clinics of North America, 1997, 26, 295-311.	1.2	41
419	Hormone Replacement Therapy in Postmenopausal Women: Urinary N-Telopeptide of Type I Collagen Monitors Therapeutic Effect and Predicts Response of Bone Mineral Density. American Journal of Medicine, 1997, 102, 29-37.	0.6	267
420	A tale of two worlds in prescribing etidronate for osteoporosis. Lancet, The, 1997, 350, 1340.	6.3	12
421	Comparative Clinical Pharmacology and Therapeutic Use of Bisphosphonates in Metabolic Bone Diseases. Drugs, 1996, 51, 537-551.	4.9	40
422	Clinical utility of bone mass measurements in adults:Consensus of an international panel. Seminars in Arthritis and Rheumatism, 1996, 25, 361-372.	1.6	80
423	Osteoporosis: Implications for elderly men. Geriatric Nursing, 1996, 17, 171-174.	0.9	1
424	The role of bisphosphonates and fluorides in the prevention and treatment of osteoporosis. Topics in Geriatric Rehabilitation, 1995, 10, 19-34.	0.2	2
425	Growth hormone, insulin-like growth factors, and the senescent skeleton: Ponce de Leon's fountain revisited?. Journal of Cellular Biochemistry, 1994, 56, 348-356.	1.2	39
426	The influence of endurance training on insulin-like growth factor-1 in older individuals. Metabolism: Clinical and Experimental, 1994, 43, 1401-1405.	1.5	80
427	Elderly women in northern New England exhibit seasonal changes in bone mineral density and calciotropic hormones. Bone and Mineral, 1994, 25, 83-92.	2.0	122
428	Health care reform in the United States: Implications for the management of patients with metabolic bone diseases. Journal of Bone and Mineral Research, 1994, 9, 595-598.	3.1	0
429	Low bone mineral density in adults with previous hypothalamic-pituitary tumors: Correlations with serum growth hormone responses to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3. Calcified Tissue International, 1993, 52, 183-187.	1.5	98
430	Primary Hyperparathyroidism in an Elderly Patient with Multiple Myeloma. Journal of the American Geriatrics Society, 1992, 40, 703-705.	1.3	12
431	In vitro resorptive activity of isolated chick osteoclasts: Effects of carbonic anhydrase inhibition. Journal of Bone and Mineral Research, 1991, 6, 61-66.	3.1	28
432	Exercise patterns and trabecular bone density in college women. Journal of Bone and Mineral Research, 1990, 5, 245-250.	3.1	105

#	Article	IF	CITATIONS
433	Age-Related Changes in Serum Insulin-Like Growth Factor-Binding Proteins in Women*. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 575-579.	1.8	102
434	T lymphocyte surface antigen markers in osteoporosis. Journal of Bone and Mineral Research, 1990, 5, 851-855.	3.1	31
435	Lipolysis of bone marrow adipocytes is required to fuel bone and the marrow niche during energy deficits. ELife, 0, 11, .	2.8	27